A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

Phase 2 Recruiting 31 enrolled Shandong Cancer Hospital and Institute The First Affiliated Hospital of Nanchang University · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.

Timeline

Start: 2023-06-01
Primary completion: 2024-12-30
Completion: 2026-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Orelabrutinib	Small molecule	150 mg	Oral
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Doxorubicin	Other / unclassified	—	—
Background	Epirubicin	Small molecule	—	—
Background	Prednisone	Other / unclassified	—	—
Background	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Background	Vincristine	Small molecule	—	—
Background	Vindesine	Small molecule	—	—

Indications

No indication recorded.